Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (1) , 115181
Abstract
No abstract availableKeywords
Funding Information
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China (81673301)
- U.S. Department of Health and Human Services
- China Pharmaceutical University (CPU2018GF02)
- National Cancer Institute
This publication has 25 references indexed in Scilit:
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideNature, 2014
- BET Bromodomain Inhibition ofMYC-Amplified MedulloblastomaClinical Cancer Research, 2014
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomainProceedings of the National Academy of Sciences, 2013
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaBlood, 2012
- RNA Polymerase II Elongation ControlAnnual Review of Biochemistry, 2012
- BET domain co-regulators in obesity, inflammation and cancerNature Reviews Cancer, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Suppression of inflammation by a synthetic histone mimicNature, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences, 2001